New Oral Anticoagulants: Benefit-Risk Profile, Recurrence Rates, and Long-term Complications in Patients Treated for Established VTE

Clinical Pulmonary Medicine, 05/02/2012

Tapson V – New oral anticoagulants that do not require injections, routine coagulation monitoring, dose adjustment, or food restrictions are currently in development and/or recently approved and may enable physicians to better control anticoagulation therapy. Several Phase III trials have reported that the direct Factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran are as effective as or superior to currently used low–molecular weight heparins or vitamin K antagonists.

Print Article Summary Cat 2 CME Report